INDIANAPOLIS, Dec. 18, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportu ...

Core Insights - Eli Lilly's obesity pill, orforglipron, has shown promising results in maintaining weight loss for patients transitioning from injections like Zepbound and Wegovy in a late-stage trial [1][3][4] Group 1: Trial Results - The phase three trial involved over 300 patients who had previously taken Wegovy or Zepbound for 72 weeks, followed by a 52-week period where they were randomized to receive either the pill or a placebo [4] - Patients switching from Wegovy regained an average of only 2 pounds, while those switching from Zepbound regained about 11 pounds by the end of the trial [5] - The pill met its primary goal of demonstrating superior weight loss maintenance compared to placebo among patients who had plateaued while on injections [4] Group 2: FDA Approval and Market Potential - Eli Lilly has filed for FDA approval of orforglipron, which has received a priority review voucher that could expedite the review process [2] - Analysts suggest that positive trial results could allow Eli Lilly to capture market share from Novo Nordisk's semaglutide products, potentially impacting the competitive landscape [7] Group 3: Safety and Tolerability - The safety profile of the pill was consistent with previous studies, with common side effects being mild-to-moderate gastrointestinal issues [8] - Discontinuation rates due to side effects were 4.8% for those switching from Wegovy and 7.2% for those switching from Zepbound [9] Group 4: Market Forecast - Analysts predict that oral medications will capture a 24% share of the global weight loss drug market by 2030, valued at approximately $95 billion [12] - Eli Lilly's pill is expected to hold a 60% share of the daily oral segment, translating to around $13.6 billion, while Novo Nordisk's oral semaglutide is projected to have a 21% share [13]

据新华社，英国《自然》杂志网站日前刊发两篇来自中国研究人员的论文，验证了中美药企联合开发 的一款降糖新药作为单药治疗和联合口服降糖药治疗的疗效和安全性。这是两项以中国2型糖尿病患 者为对象的Ⅲ期临床研究。相关结果证明，玛仕度肽在血糖控制和减重方面效果均优于安慰剂或度拉 糖肽，同时可改善多项心血管代谢、肝脏和肾脏相关指标。据介绍，玛仕度肽是中国信达生物制药集 团与美国礼来制药共同推进的一款胰高血糖素（GCG）/胰高血糖素样肽-1（GLP-1）双受体激动 剂。 ...

近日，礼来公司公布了口服雌激素受体拮抗剂imlunestrant 3期EMBER-3临床试验的最新结果。该研究 纳入既往接受过芳香化酶抑制剂（AI）联合或不联合CDK4/6抑制剂治疗，并发生疾病进展的雌激素受 体阳性（ER+）、人表皮生长因子受体2阴性（HER2–）晚期或转移性乳腺癌（MBC）患者。与内分泌 治疗相比， 在携带ESR1突变的患者中，imlunestrant单药治疗显示出有临床意义的38%疾病进展或死亡 风险的降低（中位无进展生存期PFS：5.5个月 vs 3.8个月；HR = 0.62；95% CI：0.47–0.82；名义p值 = 0.0007），且中位总生存期（OS）延长11.4个月（34.5个月 vs 23.1个月；HR = 0.60；95% CI：0.43– 0.86；p = 0.0043，未达到统计学显著性界值）。在所有患者中，imlunestrant联合阿贝西利相比 imlunestrant单药可降低疾病进展或死亡风险达41%，总生存期显示出获益趋势，并在数值上将患者至化 疗时间（TTC）延后超过一年。 来源：环球网 相关研究结果已发表于《肿瘤学年鉴》（Annals of Onco ...

Key Points These two healthcare stocks are top names to invest in, but they haven't both been doing well of late. Eli Lilly has generated $25 billion in revenue from its fast-growing GLP-1 drugs this year. Novo Nordisk, in contrast, has been facing a lot of adversity and has had to cut its guidance due to rising competition. 10 stocks we like better than Novo Nordisk › Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are two of the leading companies in the fast-growing GLP-1 weight loss market. ...

英国《自然》杂志网站日前刊发两篇来自中国研究人员的论文，验证了中美药企联合开发的一款降糖新 药作为单药治疗和联合口服降糖药治疗的疗效和安全性。 据介绍，玛仕度肽是中国信达生物制药集团与美国礼来制药共同推进的一款胰高血糖素（GCG）/胰高 血糖素样肽-1（GLP-1）双受体激动剂。 参与相关研究的信达生物制药集团综合管线首席研发官钱镭说，上述研究成果为超重、肥胖和糖尿病患 者提供了高质量的循证医学证据，也显示了中国在相关领域的科研能力。 糖尿病与肥胖密切相关，超重会加重胰岛素抵抗，是导致2型糖尿病发生、进展和并发症增加的主要因 素之一。相关并发症可累及血管、眼睛、肾脏、足部等。 （文章来源：新华网） 这是两项以中国2型糖尿病患者为对象的Ⅲ期临床研究。相关结果证明，玛仕度肽在血糖控制和减重方 面效果均优于安慰剂或度拉糖肽，同时可改善多项心血管代谢、肝脏和肾脏相关指标。 ...

据报道，礼来公司(LLY.US)将把旗下两款热销的糖尿病与减重药物——Mounjaro和Zepbound在加拿大的 售价大幅下调20%甚至更多。调整后，以四周用量计，这两款药物在加拿大市场的目录价将变为：2.5 毫克和5毫克规格的价格降至300加元(约合217美元);7.5毫克和10毫克这两种高规格的价格则降至420加 元。新价格将于12月29日起正式生效。 对此，礼来在非工作时段尚未立即回复置评请求。 截至周三收盘，该股收跌超1%，报1041.79美元。 本月早些时候，礼来已在美国下调减重药Zepbound单支小瓶装的售价，以提高美国患者的可负担性。 ...

Core Insights - Eli Lilly is reducing the prices of its diabetes and weight-loss drugs Mounjaro and Zepbound by 20% or more in Canada [1] Company Actions - The price cut is part of a strategy to make these medications more accessible to Canadian consumers [1] - The announcement was communicated to pharmacies through a note issued by the U.S.-based drugmaker [1]

"History suggests Nvidia should modestly beat Eli Lilly over the next roughly two months,†notes a DataTrek analyst — but there are some caveats ...

Follow Jack Bowman on Seeking Alpha! Follow CGDV on Seeking Alpha! This video's transcript was generated by a third party. It is not curated or reviewed and is provided for convenience and information purposes only. The accuracy and completeness of the transcript are not guaranteed. Past performance is no guarantee of future results. Content is offered for information purposes only. Unless stated otherwise, any and all individuals participating in the video are third parties that include both professional ...